Evidence map›Paper›PMID 38171510›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2024

International consensus on post-transplantation diabetes mellitus.

Adnan Sharif, Harini Chakkera, Aiko P J de Vries, Kathrin Eller, Martina Guthoff, Maria C Haller, Mads Hornum, Espen Nordheim, Alexandra Kautzky-Willer, Michael Krebs and 8 more

Abstract readConsensus Statement
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.Journal of the American Society of Nephrology : JASN · 2026
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Adnan SharifDepartment of Nephrology and Transplantation, University Hospitals Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-7586-9136
Harini ChakkeraDivision of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ, United States of America.
Aiko P J de VriesLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-9284-3595
Kathrin EllerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz Austria.ORCID 0000-0002-6214-5008
Martina GuthoffDepartment of Diabetology, Endocrinology, Nephrology, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-4294-980X
Maria C HallerOrdensklinikum Linz, Elisabethinen Hospital, Department of Medicine III, Nephrology, Hypertension, Transplantation, Rheumatology, Geriatrics, Linz, Austria.ORCID 0000-0003-4635-6291
Mads HornumDepartment of Nephrology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Espen NordheimDepartment of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Nydalen, Norway.ORCID 0000-0002-8144-0395
Alexandra Kautzky-WillerDepartment of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
Michael KrebsDepartment of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9265-7274
Aleksandra KuklaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States of America.
Amelie KurnikowskiDepartment of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Elisabeth SchwaigerDepartment of Internal Medicine, Brothers of Saint John of God Eisenstadt, Eisenstadt, Austria.
Nuria MonteroNephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, University of Barcelona, Barcelona Spain.ORCID 0000-0002-5123-4603
Julio PascualInstitute Mar for Medical Research-IMIM, Barcelona,  Spain.ORCID 0000-0002-4735-7838
Trond G JenssenDepartment of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Nydalen, Norway.
Esteban PorriniInstituto de Tecnologías Biomédicas (ITB), University of La Laguna, Research Unit Department, Hospital Universitario de Canarias, Tenerife, Spain.
Manfred HeckingDepartment of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8047-2395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplantation diabetes mellitus (PTDM) remains a leading complication after solid organ transplantation. Previous international PTDM consensus meetings in 2003 and 2013 provided standardized frameworks to reduce heterogeneity in diagnosis, risk stratification and management. However, the last decade has seen significant advancements in our PTDM knowledge complemented by rapidly changing treatment algorithms for management of diabetes in the general population. In view of these developments, and to ensure reduced variation in clinical practice, a 3rd international PTDM Consensus Meeting was planned and held from 6-8 May 2022 in Vienna, Austria involving global delegates with PTDM expertise to update the previous reports. This update includes opinion statements concerning optimal diagnostic tools, recognition of prediabetes (impaired fasting glucose and/or impaired glucose tolerance), new mechanistic insights, immunosuppression modification, evidence-based strategies to prevent PTDM, treatment hierarchy for incorporating novel glucose-lowering agents and suggestions for the future direction of PTDM research to address unmet needs. Due to the paucity of good quality evidence, consensus meeting participants agreed that making GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) recommendations would be flawed. Although kidney-allograft centric, we suggest that these opinion statements can be appraised by the transplantation community for implementation across different solid organ transplant cohorts. Acknowledging the paucity of published literature, this report reflects consensus expert opinion. Attaining evidence is desirable to ensure establishment of optimized care for any solid organ transplant recipient at risk of, or who develops, PTDM as we strive to improve long-term outcomes.

Indexed as

Diabetes MellitusKidney TransplantationOrgan TransplantationGlucoseHumansPostoperative ComplicationsRisk FactorsGlucoseGLP-1 analoguesmetabolic syndromeNODATpost-transplant diabetes mellitusSGLT2 inhibitors

Identifiers

PMID38171510
PMCPMC11024828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.